Adenocarcinoma patients with an EGFR mutation have a longer progression-free survival after treatment with the EGFR-TKI, gefitinib, as compared to standard chemotherapy [5, 6], making targeted therapy a hallmark of lung cancer treatment. The gene discussed is EGFR; the disease is adenocarcinoma.